Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction
NCT00193128Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2004
- Primary completion
- Feb 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine in esophageal cancer and gastroesophageal junction cancer (2 cohorts), sponsored by SCRI Development Innovations. Primary endpoint: Pathologic Complete Response Rate at 18 months. Started Apr 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00193128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193128.